Surge in anti-psychotics
Adramatic rise in the use of prescription drugs designed to treat severe psychiatric disorders has sparked warnings from health experts about the risk of significant side effects, if taken in high doses. The jump in antipsychotics is being attributed to aggressive marketing by drug companies and older European women using them “off label” as sleep medication or tranquilisers.
University of Otago research published today shows a 49 per cent jump in anti-psychotic prescriptions between 2008 and 2015.
More than 500,000 prescriptions were issued in the last year of research. But the sharp rise appears to outstrip any increase in the conditions the drugs are designed to treat.
One in 36 New Zealand adults, or 2.8 per cent, were prescribed anti-psychotics in the latest data. That places New Zealand around the mid-point of developed countries. Australia’s rate was lower, at 1.7 per cent. The highest rate was Taiwan, at 7.8 per cent.
The study’s author and psychiatrist Professor Roger Mulder said anti-psychotic medicines were meant for treating people with schizophrenia and bipolar disorder.
“But the most common group, actually, in terms of frequency was European women over 65 years old,” he said.
“And so what we think . . . is that a lot of the increase isn’t because people are getting increasingly psychotic. But it’s that the drugs are being used off-label for other indications — to help sleep, to help anxiety, to help tranquilise people.”
The increase in anti-psychotic medicine use was occurring around the world, and was not necessarily a bad thing, Mulder said.
The drugs can have significant side effects, including weight gain and changes to blood sugar. But the side effects are related to high doses of the drug, and people who are using them for insomnia or anxiety are likely to be on a lower dose.
“We don’t know whether they can cause the same problems at low doses — though a few reports say they
can,” Mulder said. “It’s something that needs looking at.”
The Ministry of Health’s chief adviser on mental health, John Crawshaw, welcomed the new research, saying the rise in prescriptions was a complex and concerning issue.
Carefully monitored use of antipsychotics worked well for many with schizophrenic or bipolar disorders, he said, but there was a shared
We don’t know whether they can cause the same problems at low doses — though a few reports say they can. It’s something that needs looking at. Professor Roger Mulder, study author
concern about possible over-reliance on drugs to treat these conditions.
Crawshaw said a major Government-led review of the mental health sector would provide some guidance in this area.
Medical watchdog Medsafe says there is no legal barrier to “off label” medicine use, as long as the prescribing doctor follows ethical codes and patients are informed.
The Otago study found there was no rational basis for the prescribing of anti-psychotics in New Zealand. Rates of prescription varied between regions and ethnicities.
“Which suggests it’s not just medical factors that are driving this prescription — there might be other factors as well,” Mulder said.
One of those factors could be the way the drugs are marketed by manufacturers.
The biggest growth in usage rates was for what were known as atypical, or next generation anti-psychotics, especially quetiapine and olanzapine.
Pharmaceutical companies have been taken to court in the United States for promoting off-label use of medicines such as olanzapine.
“In New Zealand, we don’t have any evidence of this,” Mulder said. “But certainly in the States, they are not allowed to market it off-label or to present it as being effective without trials being done.
“I think there’s no doubt that pharmaceutical companies have influenced prescriber choices and I think they’ve probably, certainly in the past, encouraged off-label.”